ArticleJournal of translational medicine2026
Single-cell and spatial multi-omics reveal mechanistic insights of FOLH1+ endothelial cells in clear cell renal cell carcinoma.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is the most prevalent and aggressive subtype of renal malignancy, characterized by extensive vascularization and poor prognosis. Early detection markedly improves patient outcomes, and prostate-specific membrane antigen (PSMA, encoded by FOLH1) imaging has recently emerged as a valuable diagnostic tool for ccRCC. However, the cellular source, spatial distribution, and mechanistic contribution of FOLH1 expression within the tumor microenvironment remain poorly understood.
methodsWe performed an integrative analysis combining multi-regional single-cell RNA sequencing (scRNA-seq), spatial transcriptomics (ST), and bulk RNA-seq data. Computational findings were validated using primary patient-derived endothelial cells, in vitro co-culture systems, and an in vivo syngeneic mouse model.
resultsIntegration of 191,906 single cells revealed pronounced spatial remodeling, with FOLH1 expression highly restricted to ECs. Subclustering identified a distinct FOLH1-positive endothelial cell (FOLH1+EC) population that progressively accumulated from normal kidney to tumor-core regions. Pseudotime analysis positioned FOLH1+ECs at terminal differentiation states enriched for PI3K-Akt and focal adhesion signaling. Mechanistically, we validated that FOLH1-overexpressing ECs promote RCC cell proliferation and migration via the APP-CD74 axis. APP or CD74 knockdown abrogated the tumor-promoting effect of FOLH1-overexpressing endothelial cells. Spatial transcriptomics localized FOLH1+ECs in close proximity to RCC nests, where APP and CD74 are colocalized. In a syngeneic mouse model, pharmacological inhibition of PSMA with 2-PMPA significantly suppressed tumor growth and reversed epithelial-mesenchymal transition (EMT) phenotypes. In clinical cohorts, a high FOLH1/endothelial signature (Cluster C1) was associated with angiogenic/EMT pathway activation and worse survival. Independent clinical validation further confirmed that increased endothelial PSMA expression correlates with microvascular invasion and metastatic burden.
conclusionThis study identifies and functionally characterizes a FOLH1+ endothelial population that actively reshapes tumor vascular niches via APP-CD74 signaling. Our findings provide a mechanistic basis for endothelial-restricted PSMA expression and offer preclinical proof-of-concept that targeting this axis effectively curbs ccRCC progression.
Indexed as
Identifiers
42449425What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.